Digoxin: Na+/K+ ATPase Pump Inhibitor for Cardiac and Antiviral Research

Executive Summary: Digoxin is a potent cardiac glycoside that inhibits the Na+/K+-ATPase pump, resulting in increased intracellular calcium and enhanced cardiac contractility (APExBIO). It is widely used in research on congestive heart failure, arrhythmias, and as an antiviral agent against chikungunya virus (CHIKV) in several human and animal cell models (Sun et al., 2025). Its solubility profile includes high solubility in DMSO (≥33.25 mg/mL) and insolubility in water or ethanol, which is critical for laboratory protocols. Digoxin from APExBIO (SKU B7684) is delivered at >98.6% purity, with documentation supporting HPLC, NMR, and MSDS validation. Experimental protocols recommend prompt use of prepared solutions to preserve integrity and reproducibility.

Biological Rationale

Cardiovascular diseases remain a leading cause of morbidity and mortality globally. Heart failure and arrhythmias are associated with impaired cardiac contractility and altered electrophysiology. The Na+/K+-ATPase pump regulates ionic gradients essential for cardiac action potentials and excitation-contraction coupling. Inhibition of this pump modulates intracellular sodium and calcium, directly affecting cardiac output and rhythm (see Digoxin Redefined). Digoxin, a well-established cardiac glycoside, is central to dissecting these mechanisms in both clinical and preclinical settings. Recently, Digoxin has also been identified as an inhibitor of chikungunya virus infection, expanding its utility beyond traditional cardiovascular research (see Digoxin: Cardiac Glycoside for Heart Failure and Antiviral Research). This article updates previous overviews by integrating pharmacokinetic and practical workflow considerations.

Mechanism of Action of Digoxin

Digoxin binds to the extracellular domain of the Na+/K+-ATPase pump, primarily in cardiac myocytes. This inhibition increases intracellular sodium, which reduces sodium-calcium exchange activity and raises cytosolic calcium. Elevated calcium augments contractile force (positive inotropy). In arrhythmia models, Digoxin modulates vagal tone and action potential duration. In virology, Digoxin disrupts viral entry and replication, particularly for CHIKV, possibly by perturbing ionic homeostasis required for viral lifecycle progression (APExBIO). The precise antiviral mechanism remains under active investigation, with dose- and cell-line-specific effects reported.

Evidence & Benchmarks

• Digoxin increases cardiac output and reduces right atrial pressure in canine heart failure models after intravenous doses of 1–1.2 mg (APExBIO, product page).
• In human cell lines (U-2 OS), primary human synovial fibroblasts, and Vero cells, Digoxin impairs chikungunya virus (CHIKV) infection in a dose-dependent manner at 0.01–10 μM (Sun et al., 2025).
• Digoxin’s solubility in DMSO is ≥33.25 mg/mL, while it is insoluble in water and ethanol, requiring DMSO as a vehicle for in vitro and in vivo studies (APExBIO).
• Quality control of APExBIO’s Digoxin (SKU B7684) includes HPLC, NMR, and MSDS documentation, supporting >98.6% purity for reproducible research (see Practical Solutions for Assay Reproducibility).
• Animal studies demonstrate that intravenous Digoxin rapidly achieves pharmacodynamic effects, with improved cardiac contractility and hemodynamics compared to controls (APExBIO, product page).
• Pharmacokinetic and transporter-based studies in related glycoside research highlight the impact of disease state and metabolism on tissue distribution and efficacy (Sun et al., 2025, Table 2).

Applications, Limits & Misconceptions

Digoxin is widely utilized in:

• Cardiac contractility and arrhythmia research, as a model Na+/K+-ATPase inhibitor.
• Congestive heart failure animal models, to validate inotropic and hemodynamic endpoints.
• Antiviral screening, especially against chikungunya virus in various cell lines.
• Pharmacokinetic and transporter studies, including assessment of glycoside distribution and metabolism.

This article clarifies the mechanistic scope, workflow parameters, and emerging antiviral evidence, extending the translational context outlined in Digoxin at the Translational Frontier, by providing updated solubility, dosing, and cell model data.

Common Pitfalls or Misconceptions

• Digoxin is not soluble in water or ethanol; using these solvents can result in precipitation and unreliable dosing.
• Long-term storage of Digoxin solutions is discouraged; freshly prepared solutions ensure reproducibility.
• Antiviral efficacy against CHIKV is cell line- and concentration-dependent; results may not generalize to all viruses or in vivo systems.
• Therapeutic dosing in animal models cannot be directly extrapolated to humans without dedicated pharmacokinetic studies.
• Digoxin is not a broad-spectrum antiviral; its effect is documented primarily against CHIKV and related models.

Workflow Integration & Parameters

For laboratory use, APExBIO’s Digoxin (SKU B7684) should be stored as a solid at room temperature. Solutions are best prepared in DMSO at ≥33.25 mg/mL and used immediately. Typical in vitro concentrations for CHIKV inhibition range from 0.01 to 10 μM; cardiac research protocols may require dosing adjusted for animal weight and administration route. Quality control documents (HPLC, NMR, MSDS) are provided to ensure transparency and reproducibility. Experimental rigor is supported by referencing validated batch data and following recommended handling schedules. For more practical assay guidance, see Digoxin (SKU B7684): Practical Solutions for Assay Reproducibility, which details troubleshooting and optimization scenarios not covered in this article.

Conclusion & Outlook

Digoxin remains a cornerstone in cardiac glycoside and Na+/K+ ATPase pump inhibitor research, with expanding relevance in antiviral screening. APExBIO’s Digoxin (SKU B7684) provides high-purity, quality-controlled reagent for diverse experimental paradigms. Ongoing research is refining its mechanistic scope and pharmacokinetic integration, especially in disease state models and complex cellular systems. For further reading on mechanistic precision, see Digoxin as a Translational Powerhouse, which contrasts broader pharmacokinetic trends with the practical, workflow-oriented update provided here. For ordering and documentation, refer to the official APExBIO Digoxin product page.